UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000015001
Receipt number R000017447
Scientific Title Convection enhanced delivery using ACNU and oral temozolomide therapy to treat recurrent spinal anstrocytoma
Date of disclosure of the study information 2014/09/01
Last modified on 2019/03/05 22:45:15

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Convection enhanced delivery using ACNU and oral temozolomide therapy to treat recurrent spinal anstrocytoma

Acronym

ACNU CED for recurrent spinal astrocytoma

Scientific Title

Convection enhanced delivery using ACNU and oral temozolomide therapy to treat recurrent spinal anstrocytoma

Scientific Title:Acronym

ACNU CED for recurrent spinal astrocytoma

Region

Japan


Condition

Condition

spinal cord astrocytoma

Classification by specialty

Neurosurgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Examine whether ACNU CED treatment is safe for recurrent spinal astrocytoma

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Determine maximum tolerable concentration of ACNU

Key secondary outcomes

Effectiveness, survival rate of 6 months, and overall survival


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Catheter implantation (day1)
ACNU (0.25 mg/ml or lower)+ Gd-DOTA(1mM) infusion (day1-2) and TMZ (200mg/m2) p.o. (day1-5)

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) For those who suffer recurrent spinal cord astrocytoma and surgical treatment is not indicated. Cases include spinal cord originated tumors and disseminated lesion from intracranial astrocytoma.
2) For those who suffered recurrence after standard treatments including surgical removal, radiotherapy and chemotherapy.
3) For those who did not undertake any of the above mentioned treatment during the previous 4 weeks.
4) For those who have normal laboratory checkup.
5) For those who gave consent to be included in the exam.

Key exclusion criteria

1) For those suffering other cancer
2) For those suffering meningitis or pneumonia
3) Pregnant or Lactating women
4) For those suffering inflammation
5) For those suffering liver dysfunction
6) For those suffering myelo -suppression
7) For those suffering kidney dysfunction
8) For those having bleeding tendency or undertaking anti-coagulation or anti-platelet therapy
9) For those suffering psychiatric disorder
10) For those suffering uncontrolled Diabetes mellius
11) For those who have history of cardiac infarction in the last three months, or suffering angina pectoralis
12) For those having history of Idiopathic pulmonary fibrosis or interstitial pneumonia

Target sample size

15


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Teiji Tominaga

Organization

Tohoku University Graduate School of Medicine

Division name

Neurosurgery

Zip code


Address

1-1 Seiryo Aoba Sendai Japan

TEL

022-717-7230

Email

profTT@nsg.med.tohoku.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Toshiki Endo

Organization

Tohoku University Graduate School of Medicine

Division name

Neurosurgery

Zip code


Address

1-1 Seiryo Aoba Sendai Japan

TEL

022-717-7230

Homepage URL

http://www.nsg.med.tohoku.ac.jp/medical/id=55

Email

endo@nsg.med.tohoku.ac.jp


Sponsor or person

Institute

Tohoku University, Graduate school of medicine, Department of Neurosurgery

Institute

Department

Personal name



Funding Source

Organization

Tohoku University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 09 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2011 Year 09 Month 09 Day

Date of IRB


Anticipated trial start date

2011 Year 09 Month 09 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 08 Month 30 Day

Last modified on

2019 Year 03 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017447


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name